Organic anion transporters (OATs) are important in the renal secretion, and thus the clearance, of many drugs; and their functional change can result in pharmacokinetic variability. In this study, we applied transport rates measured in vitro using OAT-transfected human embryonic kidney cells to predict human renal secretory and total renal clearance of 31 diverse drugs. Selective substrates to OAT1 (tenofovir), OAT2 (acyclovir and ganciclovir) and OAT3 (benzylpenicillin, oseltamivir acid) were used to obtain relative activity factors (RAFs) for these individual transporters by relating in vitro transport clearance (after physiological scaling) to in vivo secretory clearance. Employing the estimated RAFs -0.64, 7.3 and 4.1 for OAT1, OAT2 and OAT3, respectively -and the in vitro active clearances, renal secretory clearance and total renal clearance were predicted with an average fold error (AFE) of 1.89 and 1.40, respectively. The results show that OAT3-mediated transport play predominant role in the renal secretion for 22 of 31 drugs evaluated. This mechanistic static approach was further applied to quantitatively predict renal drug-drug interactions (AFE ~1.6) of the substrate drugs with probenecid, a clinical probe OAT inhibitor. In conclusion, the proposed static in vitro-in vivo extrapolation approach is the first comprehensive attempt towards mechanistic modeling of renal secretory clearance based on routinely employed in vitro cell models.
INTRODUCTION
Accurate prediction of human pharmacokinetic properties during the drug design stage is very important to identify and progress candidate molecules that can be successful in the clinic (Hosea et al., 2009; Di et al., 2013) . With the improved understanding in metabolic biotransformation pathways, medicinal design teams are able to achieve good metabolic stability; however, such chemical space may likely possess transporter-mediated disposition as the major clearance mechanism -hepatic uptake and renal clearance (Varma et al., 2015) .
Kidney plays a key role in the detoxification of xenobiotics and endogenous products (Russel et al., 2002; Lee and Kim, 2004; Feng et al., 2010) . In an analysis of 391 drugs with human clearance data available, ~31% (123 compounds) showed predominant renal elimination contribution (i.e., renal clearance more than 50% of total body clearance), implying the need for renal clearance projections in drug discovery (Varma et al., 2009 ). Renal elimination is the net result of several processes, involving glomerular filtration, active secretion and tubular reabsorption, and possibly renal metabolism (Russel et al., 2002; Lee and Kim, 2004; Feng et al., 2010; Morrissey et al., 2013) . Glomerular filtration is a unidirectional passive process that occurs for most small molecules (MW<5000 Da) regardless of their ionization state. Renal secretion is a process where transporters actively secrete compounds into the renal tubule. Solute Carrier Family 22A (SLC22A) transporter system, which include organic anion transporters (OATs) and organic cation transporters (OCTs), predominantly govern this process (Lee and Kim, 2004; Feng et al., 2010; Morrissey et al., 2013) . Localized on the basolateral membrane of the proximal tubules, OAT1/2/3 and OCT2 are involved in the uptake of drugs, and are associated with clinical DDIs (Morrissey et al., 2013) . On other hand, tubular reabsorption often depends on the passive permeability of compounds (Varma et al., 2009; Scotcher et al., 2016) . 
DMD # 074294
Allometric scaling using animal data is widely applied for extrapolating the pharmacokinetic parameters, including renal clearance, to predict clinical pharmacokinetics (Paine et al., 2011) . Such scaling methodology may be useful for drugs that are eliminated in the urine by glomerular filtration process. However, allometry is not a reliable methodology for drug cleared predominantly by transporter-mediated active process because of possible species difference in transporter expression and function (Chu et al., 2013) . Prediction of active secretion is limited by lack of established in vitro-in vivo extrapolation (IVIVE) methodologies. Secretion of ionic drugs involves basolateral uptake and subsequent efflux across the apical membrane into the urine. However, the renal uptake clearance of anionic drugs is typically similar to renal secretory clearance with uptake often being the ratedetermining process (Sirianni and Pang, 1997; Watanabe et al., 2011; Varma et al., 2015) .
Therefore, establishing IVIVE of basolateral uptake clearance alone could provide quantitative prediction of renal secretory clearance.
Our goal is to establish an IVIVE method based on relative activity factor (RAF) to predict human renal clearance of OAT substrates using in vitro transport data. Transporterspecific uptake clearance was measured in human embryonic kidney (HEK)293 cells singly transfected with human OAT1, OAT2 and OAT3, and scaled to in vivo secretory clearance via RAFs -established using selective substrates. This bottom-up approach was further extended to predict OAT-mediated drug interactions with probenecid, a recommended probe inhibitor.
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Clinical data collection
Human renal clearance and the plasma fraction unbound of the drugs were primarily taken from our previous compilations Varma et al., 2009; Lombardo et al., 2014) and additional literature publications. Where available, human blood-to-plasma (BP) ratio was extracted from literature or from internal database. BP ratio was assumed to be 0.55 for anionic drugs and 1 for non-acidic drugs when the experimental data was not available.
However, no significant impact of BP ratio was noted on the overall predictions. DDI (percentage change in renal clearance) data was collected primarily from University of Washington drug interaction database (https://www.druginteractioninfo.org) and additional Pubmed search. 
Transport studies using OATs transfected HEK293 cells
Large batches of cryopreserved OATs-transfected and wild-type HEK293 cells were prepared and validated for their transport activity before and after batch preparation. All the uptake studies were carried out using the same batch of cells per cell type according to the procedures reported earlier (Feng et al., 2008; Cheng et al., 2012 (Poirier et al., 2008) .
Equations 1-6 are used in this modeling process:
and, 
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This article has not been copyedited and formatted. The final version may differ from this version. Renal blood clearance (CL renal,b ) is determined by glomerular filtration, tubular secretion, and reabsorption processes, and can be mathematically described by (Russel et al., 2002; Feng et al., 2010) :
Where, f u,b is unbound fraction in blood, GFR is glomerular filtration rate, CL sec is renal secretory clearance and F reabs is the fraction of filtered and secreted drug that is reabsorbed.
CL renal,b is equal to renal plasma clearance (CL renal,p ) divided by blood-to-plasma ratio. For the majority of compounds tested in this study, passive permeability or passive transport clearance is very low and so the F reabs was assumed to be negligible (see Results and Discussion). Assuming a well-stirred model, CL sec is expressed as (Eq. 8):
Where Q r is the renal blood flow (15.7 mL/min/kg (Davies and Morris, 1993) ) and CL int,sec is the intrinsic secretory clearance obtained from in vitro uptake studies. In vitro active uptake clearance (µL/min/mg-protein) mediated by each OAT was corrected using physiological scalars to obtain in vitro scaled CL int,OATx in the units of mL/min/kg: 0. (Davies and Morris, 1993; Imamura et al., 2011; Watanabe et al., 2011 Prediction of change in renal clearance in the presence of probenecid, a recommended probe inhibitor for OATs-based interactions, was calculated using the following set of equations.
CL' int,sec and CL' sec are intrinsic secretory and overall secretory clearance in the presence of the inhibitor drug, respectively. IC 50 is the inhibition constant and C max,u is the maximum unbound plasma concentration of inhibitor drug.
Model Predictability
Prediction bias and precision were assessed with average fold error (AFE) Eq. 14.
(Eq. 14)
N is the number of observations. 
RESULTS

In vitro transport of OAT substrates
Uptake of 31 drugs was evaluated in wild-type and transporter-transfected HEK293 cell expressing OAT1, OAT2 and OAT3. Tenofovir showed selective uptake by OAT1-transfectd cells, while its uptake by OAT2-and OAT3-transfected cells was not significantly (F-test with α-value of 0.05) different from the uptake by wild-type cells. Similarly, acyclovir and ganciclovir showed selective uptake by OAT2. Benzylpenicillin (penicillin G) and oseltamivir acid were selectively transported by OAT3 (Fig. 1 ). Data were fitted to a twocompartment model to estimate the transporter-mediated active uptake clearance (CL int,OAT ) and passive uptake clearance (CL pass ). Table 1 . shows the estimated uptake clearance of the 5 selective substrates as well as other 26 compounds evaluated in this study. The in vitro active uptake clearance was scaled to obtain the in vivo value per body weight using the physiological scaling factors. Using the selective substrates, relative activity factors (RAFs) were derived to bridge the difference between the scaled in vitro uptake clearance and the in vivo intrinsic secretory clearance for each transporter. The obtained RAFs are 0.64, 7.3 and 4.1 for OAT1, OAT2 and OAT3, respectively.
Prediction of active secretion and renal clearance
Secretory intrinsic clearance (CL int,sec ) and the renal plasma clearance predicted using the transport data and the obtained RAFs showed good agreement to the observed values (Fig. 2) . The predicted CL int,sec and renal clearance are within 2-fold for 68% and 84% of the observed values, respectively, for the 31 compounds evaluated. Acetazolamide, adefovir, bumetanide, pravastatin, rosuvastatin and zalcitabine are notable outliers, while the predicted intrinsic secretory clearance for other 25 compounds were within 3-fold of the observed (Fig 2A) . Acetazolamide is the only compound showing >3-fold underprediction of renal clearance (Fig. 2B) . 
Permeability -tubular reabsorption relationship
Using a separate dataset of 47 compounds with human renal plasma clearance lower than f u,p •GFR (Supplementary Table 1 ), an empirical relationship between fraction reabsorbed
and apparent permeability (P app ) across MDCK-low efflux cells (pH 6.5) was derived. Permeability values were obtained from our previous work (Varma et al., 2012) . We applied sigmoidal model [F reabs = P app a /(b a + P app a ), where 'a' represents the slope factor and 'b' is the value of P app at which F reabs equals 0.5] that was previously reported (Scotcher et al., 2016) . Similar to the finding of Scotcher et al. (Scotcher et al., 2016) , no correlation was seen for basic drugs. However, a significant correlation (r 2 =0.9) was noted for the combined set of acids, neutral and zwitterions (n=31), with the estimated values of 2.9 ± 0.6 and 6.0 ± 0.5 x10 -6 cm/sec for 'a' and 'b', respectively (Fig.   4A ). On the basis of this relationship, we note that the tubular reabsorption of majority of compounds (28 of 31) in the OATs (renal secretory) dataset is <0.15 (Fig. 4B) .
Prediction of renal DDIs with probenecid
In vitro inhibition studies showed concentration-dependent inhibition of OAT1-mediated PAH uptake and OAT3-mediated E3S uptake by probenecid with the estimated IC 50 values of 9.6 µM and 4.5 µM, respectively (Fig. 5) . Probenecid also inhibited OAT2- (Selen et al., 1982) adjusted for concentration-dependent plasma unbound fraction (Emanuelsson et al., 1987) . Hence, free C max values of 6.2 µM, 15 µM, 24.4 µM and 51 µM were used for the corresponding perpetrator (probenecid) dose of 500 mg, 750 mg, 1000 mg and 1500 mg, respectively. Clinical data of change in renal clearance when dosed in combination with probenecid were extracted from the published literature, for the OATs substrates evaluated in the in vitro rate study. A total of 18 clinical interactions with probenecid as an inhibitor drug were evaluated with the mechanistic DDI model (Eq. 11-13), which captured the filtration and secretory components of the victim drug and interaction at the level of three OAT isoforms. Predicted change in renal clearance was within ±40% of the observed mean value for 16 of 18 (89%) cases, with an AFE of 1.66, when using this mechanistic static model (Fig. 6) . Acyclovir, which is predominantly transported by OAT2, is the only false negative prediction (predicted <25% and observed ≥25%).
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DISCUSSION
Renal clearance determines the pharmacokinetics of several drugs, particularly
Extended clearance classification system (ECCS) class 3A, 3B and 4 drugs (Varma et al., 2009; Varma et al., 2015) . However, methodologies to predict renal clearance are limited with allometirc scaling of dog or rat renal clearance suggested to be a potential option (Paine et al., 2011 Of the drugs evaluated in OAT1, OAT2 and OAT3 substrate assays, tenofovir was identified as selective substrate to OAT1, while acyclovir and ganciclovir behaved as OAT2 selective substrates. Benzyl penicillin and oseltamivir acid were selective to OAT3, with no measurable active uptake in the OAT1-and OAT2-transfected cells (Fig. 1 ). These observations are generally consistent with the earlier reports (Cheng et al., 2012; Maeda et al., 2014) . RAFs -bridging the in vitro and in vivo human intrinsic secretory clearance after correcting for the physiological scalars -were obtained using these selective substrates. The
RAF values represent a collated correction for the (i) differences in the transporter expression levels between the in vitro transfected cells and proximal tubule cells, (ii) in vitro-in vivo 15
This article has not been copyedited and formatted. The final version may differ from this version. ECCS framework suggests that drugs with low passive permeability are likely cleared by urinary route (>70% of the systemic clearance), with the exception of high molecular weight (>400Da) acids or zwitterions (Class 3B); in which case, hepatic uptake may be the ratedetermining process to the systemic clearance (Varma et al., 2015) . Therefore, ECCS
provides an early indication of the potential contribution of the renal clearance to the total body clearance and the renal DDI liability, which needs to be followed up with quantitative predictions. Availability of IVIVE methodologies for quantitative predictions is very limited.
Watanabe et al., applied IVIVE approach based on in vitro uptake clearance by human kidney slices to predict secretory renal clearance for a set of 10 anionic drugs and showed good predictability (Watanabe et al., 2011) . However, such methodology is limited by availability of human kidney tissue. Kunze et al., used in vitro bidirectional permeability across LLC-PK1 cells to establish a model incorporating both active secretion and tubular reabsorption to predict renal clearance of about 20 drugs (Kunze et al., 2014) . Although simple and amenable to high throughput screening platforms, the later methodology, which assumes that LLC-PK1 cells (derived from pig kidney epithelium) quantitatively express all relevant uptake and efflux transporters as in human proximal tubule cells, may potentially mispredict active secretion. For example, LLC-PK1 cells show limited OAT activity and may underestimate active transport for acids and zwitterions (Hori et al., 1993 vitro, although uptake into cell compartment is often the rate-determining step in the secretory clearance (Watanabe et al., 2011; Posada et al., 2015) . Use of established scaling factors for predicting in vivo clearance from the recombinant systems is a well proven practice for metabolic pathways (Obach et al., 1997) . However, such IVIVE approaches are very limited for transporter-mediated clearance. Posada et al., applied initial rate data obtained from OAT3-transfected cells to develop a middle-out PBPK model to recover renal clearance of a single substrate drug, pemetrexed (Posada et al., 2015) . To the best knowledge, the current study represents the first comprehensive attempt to establish IVIVE methodology for prospective translation of transport data based on stably transfected cell systems to quantitatively predict transporter-mediated renal clearance and DDIs.
The proposed IVIVE approach relies on certain assumptions, which needs careful consideration on its application. Primarily, the renal clearance of the drugs assessed here was assumed to be driven by glomerular filtration and tubular secretion process with no tubular reabsorption. It is generally believed that reabsorption is associated largely with passive transport along the length of nephron. We therefore, used an apparent relationship between transcellular permeability and fraction reabsorbed (P app -F reabs correlation) (Scotcher et al., 2016) , to demonstrate that tubular reabsorption has a minimal role in the renal clearance of drugs in our dataset (Fig. 4) . A separate dataset of compounds with renal clearance lower than glomerular filtration (i.e. net reabsorption) was developed, and P app -F reabs correlation was established using transcellular permeability measured in low efflux MDCK cells (Varma et al., 2012) . Based on this relationship, we note that most of the compounds in the OATs IVIVE dataset are predicted to have F reabs of less than 0.15 (Fig 4B) , and thus reabsorption was not considered in the overall renal clearance predictions. However, static or dynamic reabsorption models may be applied in conjunction to the active secretion translation to predict renal clearance of compounds with high permeability (Scotcher et al., 2016) . It should be emphasized that renal clearance contribution to the total body clearance is generally <30%
for moderate and high permeable drugs (P app >5x10 -6 cm/sec), as defined by BDDCS and ECCS (Wu and Benet, 2005; Varma et al., 2012; Varma et al., 2015) ; and therefore, need for early prediction of renal clearance in this space is generally less. Secondly, we assumed that unidirectional transport across basolateral membrane of proximal tubule cells, but not apical membrane, is the rate-determining step for the secretory clearance (i.e. loss from the blood compartment). Although some of the evaluated compounds are known substrates to efflux transporters on the apical membrane of proximal tubule cells (Supplementary Table 2 ), this assumption is generally accepted, particularly for OAT substrates (Sirianni and Pang, 1997; Watanabe et al., 2011; Varma et al., 2015) . Finally, it was also assumed that the tubular secretion is determined by OATs-mediated transporter only, while other SLCs on the basolateral membrane of proximal tubule has minimal role. Based on the available literature and our internal data these drugs are not substrates to the other clinically relevant transporter (OCT2), with the exception of cimetidine and famotidine (Supplementary Table 2 ).
Nevertheless, RAF for OCT2 can also be established adopting the approach described here for OATs. Other basolateral transporters, such as OATP4C1, may also contribute to the renal secretion of certain drugs (Mikkaichi et al., 2004) ; however, limited data is available on the OATP4C1 transport activity for the 31 compounds evaluated here. Yet challenging, quantitative understanding of the contribution of other basolateral uptake transporters and apical efflux and reabsorption transport on the clearance from the blood compartment may further improve the predictions.
Recent reports suggest role of OAT2 in the renal secretion of creatinine (Lepist et al., 2014) and some antiviral drugs (Cheng et al., 2012) . We assessed the contribution of OAT2
to renal clearance of the compounds in our dataset (Fig. 3) . Interestingly, only acyclovir, ganciclovir, penciclovir and ketorolac showed significant OAT2-mediated transport, with (Shen et al., 2015) and free C max (0.7 µM), it may only cause ~30% inhibition of OAT2 at its therapeutic dose.
In conclusion, to our best knowledge this is the first report providing a comprehensively validated IVIVE method that allows for quantitative prediction of human 
